OrsoBio is focused on developing innovative therapies to address severe metabolic disorders such as obesity, type 2 diabetes, severe dyslipidemias, and non-alcoholic steatohepatitis (NASH). The company employs a multi-faceted approach targeting key metabolic pathways to restore energy homeostasis. Their pipeline includes several promising compounds: TLC-3595, a selective inhibitor of Acetyl-CoA Carboxylase 2 (ACC2), which aims to enhance insulin sensitivity in type 2 diabetes; TLC-2716, an inverse agonist of Liver X Receptor (LXR) designed to improve lipid profiles in patients with severe dyslipidemias; and various mitochondrial protonophores (TLC-6740, TLC-1235) that increase energy expenditure and metabolic health in conditions like obesity and lipodystrophies. Additionally, the ACMSD inhibitor targets NAD+ biosynthesis to enhance mitochondrial function in patients with organ dysfunction.

The therapeutic strategies employed by OrsoBio are grounded in a deep understanding of cellular energetics and metabolic regulation. By modulating fundamental pathways, such as fatty acid oxidation and cholesterol homeostasis, these therapies aim to address the root causes of metabolic disorders rather than just their symptoms. The company’s commitment to advancing first-in-class treatments is supported by a team of experienced scientists and clinicians, ensuring a robust approach to tackling the significant unmet medical needs in this field. Through their innovative pipeline, OrsoBio seeks to redefine the treatment landscape for patients suffering from severe metabolic conditions.

United States

OrsoBio, Inc. is a privately held, clinical-stage biopharmaceutical company dedicated to developing therapies to treat severe metabolic disorders, including type 2 diabetes, severe dyslipidemias, lipodystrophies, and nonalcoholic steatohepatitis. OrsoBio currently has four programs in clinical and preclinical development with first-in-class compounds that address central pathways in energy metabolism.

OrsoBio

Company Details